LIPID AND LIPOPROTEIN METABOLISM IN ATHEROSCLEROSIS (CORE A)

动脉粥样硬化中的脂质和脂蛋白代谢（核心 A）

• 批准号: 7717969
• 负责人: Alan M Fogelman
• 金额: $ 3.85万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717969
• 关键词: Anti-Inflammatory Agents; Anti-inflammatory; Ants; Atherosclerosis; Cholesterol; Computer Retrieval of Information on Scientific Projects Database; Coronary Arteriosclerosis; Coronary artery; Funding; Grant; High Density Lipoprotein Cholesterol; High Density Lipoproteins; Individual; Inflammatory; Institution; Lipids; Lipoproteins; Metabolism; Myocardial Infarction; Persons; Population; Research; Research Personnel; Resources; Risk; Source; United States National Institutes of Health; oxidation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In general HDL (the "good cholesterol") is inversely correlated for risk for coronary artery disease (i.e. the more HDL a person has, the less likely it is that the person will have coronary artery disease). However, while this is true for populations, in fact about 40 to 45% of all heart attacks occur in subjects with perfectly normal HDL levels. Our preliminary research has shown that HDL from normal individuals (.i.e those without known coronary artery diseas) is able to inhibit lipid oxidation and is ant-inflammatory. In contrast, we have found in this preliminary research that individuals with normal HDL-cholesterol levels who have coronary artery disease almost always have HDL that is dysfunctional. Their HDL is less able to inhibit lipid oxidation and in fact may actually promote lipid oxidation and instead of being anti-inflammatory, their HDL is pro-inflammatory.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 一般来说，高密度脂蛋白(“好胆固醇”)与冠状动脉疾病的风险呈负相关(即一个人的高密度脂蛋白越多，他患冠状动脉疾病的可能性就越小)。然而，虽然这在人群中是正确的，但事实上，大约40%到45%的心脏病发作发生在高密度脂蛋白水平完全正常的受试者中。我们的初步研究表明，正常人(即那些没有已知冠状动脉疾病的人)的高密度脂蛋白能够抑制脂质氧化，具有抗炎作用。相比之下，我们在这项初步研究中发现，高密度脂蛋白-胆固醇水平正常的冠心病患者几乎总是高密度脂蛋白功能障碍。他们的高密度脂蛋白抑制脂质氧化的能力较弱，实际上可能会促进脂质氧化，而且他们的高密度脂蛋白不是抗炎的，而是促炎的。